The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
ACTIVE_NOT_RECRUITING
Status
Conditions
- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
Interventions
- DRUG: Ponatinib 30mg OD
- DRUG: Ponatinib 45mg OD
Sponsor
Otsuka Beijing Research Institute